TY - JOUR T1 - Microbial contamination of hematopoietic progenitor cell products: clinical outcome Y1 - 2007 A1 - Patah,P. A. A1 - Parmar,S. A1 - McMannis,J. A1 - Sadeghi,T. A1 - Karandish,S. A1 - Rondon,G. A1 - Tarrand,J. A1 - Champlin,R. A1 - de Lima,M. A1 - Shpall,E. J. KW - Antibiotic Prophylaxis / methods KW - Bacteremia / prevention & control KW - Blood Component Removal / methods KW - Cross Infection / microbiology / prevention & control KW - Hematopoietic Stem Cell Transplantation / adverse effects KW - Hematopoietic Stem Cells / microbiology KW - Humans KW - Medical Audit KW - Retrospective Studies KW - Texas KW - Transplantation, Autologous KW - Transplantation, Homologous AB - We reviewed the results of routine microbiological assays of 3078 infused hematopoietic progenitor cell (HPC) products for autologous and allogeneic transplantation between January 2001 and December 2005. Thirty-seven (1.2%) contaminated products were found. All patients receiving contaminated infusions received empirical antibiotic prophylaxis according to the assay result. None of these patients developed a positive blood culture with the same agent, developed infections that could be attributable to the contaminated product or experienced any clinical sequelae. Coagulase-negative Staphylococcus was found in 32 (86.5%) products. Admission lengths and time to engraftment were within the expected time frame for autologous and allogeneic transplants. Microbial contamination of HPC products occurs at a low frequency; prophylactic use of antibiotics based on the microbiological assay appears to be effective in preventing clinical complications. CY - England VL - 40 CP - 4 N1 - JID: 8702459; 2007/06/18 [aheadofprint]; ppublish L2 - Journal Article; IM ID - 1778 ER -